ArticleClinical ophthalmology (Auckland, N.Z.)2026
Early Safety and Efficacy Outcomes of a Novel 360° Canaloplasty Device in Open-Angle Glaucoma: A Retrospective Cohort Study.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the safety profile and clinical efficacy of the VIA360™ Surgical System (VIA360) for ab-interno canaloplasty in the management of glaucoma. Methods: This retrospective, noncomparative chart review included 64 eyes undergoing standalone VIA360 ABiC (VIA360-Alone) or VIA360 combined with cataract surgery (VIA360-Cataract) between March 13, 2025, and January 7, 2026. Surgical success was defined as ≥20% intraocular pressure (IOP) reduction at the last follow-up without surgical reintervention. Changes in IOP, glaucoma medications, and best-corrected visual acuity (BCVA) were evaluated through 6 months. Results: At 6 months, mean IOP decreased from 18.46 to 14.07 mmHg (-4.39 mmHg; -23.78%; P < 0.0001). In subgroup analysis, VIA360-Cataract eyes showed a reduction from 17.61 to 13.48 mmHg (-4.13 mmHg; -23.45%; P = 0.0011), while VIA360-Alone eyes decreased from 20.61 to 16.15 mmHg (-4.46 mmHg; -21.69%; P = 0.0549). Glaucoma medication use also decreased from 1.46 to 1.13 medications (-22.6%; P = 0.1331) overall at 6 months, with greater reductions observed in the combined group compared with standalone cases. Surgical success was achieved in 15 of 29 eyes (51.72%) with available follow-up. No intraoperative complications or vision-threatening adverse events were observed. Conclusion: These findings suggest that VIA360 provides clinically meaningful IOP reduction with an excellent safety profile in early postoperative outcomes, demonstrating greater consistency when performed in conjunction with cataract surgery. Larger prospective studies are warranted to further define long-term durability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.